0 results available. Select is focused ,type to refine list, press Down to open the menu,
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto R...
The following section summarizes insights on Aurobindo Pharma Ltd.'s Debt / Common Equity:
We've identified the following companies as similar to Aurobindo Pharma Ltd. because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Debt / Common Equity in the risk category include:
A ratio that measures the level of the debt relative to the book value of common equity.
Debt / Equity is defined as:
Total Debt
(/) Total Common Equity
(=) Debt / Equity
Debt / Equity for Aurobindo Pharma is calculated as follows:
Total Debt [ 84.272 B]
(/) Total Common Equity [ 308.8 B ]
(=) Debt / Equity [ 27.3% ]
The tables below summarizes the trend in Aurobindo Pharma’s Debt / Equity over the last five years:
| Fiscal Year | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2020-03-31 | 59.373 B | 168.2 B | 35.3% |
| 2021-03-31 | 53.391 B | 219.3 B | 24.3% |
| 2022-03-31 | 28.513 B | 245.8 B | 11.6% |
| 2023-03-31 | 52.862 B | 268.4 B | 19.7% |
| 2024-03-31 | 66.476 B | 298.4 B | 22.3% |
The tables below summarizes the trend in Aurobindo Pharma’s Debt / Equity over the last four quarters:
| Fiscal Quarter | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2024-03-31 | 66.476 B | 298.4 B | 22.3% |
| 2024-06-30 | 66.476 B | 298.4 B | 22.3% |
| 2024-09-30 | 84.272 B | 308.8 B | 27.3% |
| 2024-12-31 | 84.272 B | 308.8 B | 27.3% |
The higher the ratio, the more debt the company has in its capital structure.
Read More on HBR: Debt / Equity Ratio
The chart above depicts the distribution of debt / common equity for companies operating in the Healthcare sector in the Developing economic region. Over 1,160 companies were considered in this analysis, and 1,123 had meaningful values. The average debt / common equity of companies in the sector is 32.3% with a standard deviation of 44.0%.
Aurobindo Pharma Ltd.'s Debt / Common Equity of 27.3% ranks in the 61.6% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developing |
| Total Constituents | 1,169 |
| Included Constituents | 1,123 |
| Min | -59.5% |
| Max | 279.3% |
| Median | 16.3% |
| Mean | 32.3% |
| Standard Deviation | 44.0% |
You can find companies with similar debt / common equity using this stock screener.